Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease
Authors
Keywords
-
Journal
NEPHROLOGY DIALYSIS TRANSPLANTATION
Volume 35, Issue Supplement_1, Pages i13-i23
Publisher
Oxford University Press (OUP)
Online
2019-10-20
DOI
10.1093/ndt/gfz237
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Delayed ischemic contracture onset by Empagliflozin associates with NHE-1 inhibition and is dependent on insulin in isolated mouse hearts
- (2019) Laween Uthman et al. CARDIOVASCULAR RESEARCH
- Empagliflozin Contributes to Polyuria via Regulation of Sodium Transporters and Water Channels in Diabetic Rat Kidneys
- (2019) Sungjin Chung et al. Frontiers in Physiology
- Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
- (2019) Jennifer R Donnan et al. BMJ Open
- SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses
- (2019) Theodosios D. Filippatos et al. POSTGRADUATE MEDICINE
- SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
- (2019) Pantelis Sarafidis et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
- (2019) David R. Matthews et al. DIABETOLOGIA
- Empagliflozin enhances human and murine cardiomyocyte glucose uptake by increased expression of GLUT1
- (2019) Julian Mustroph et al. DIABETOLOGIA
- International Consensus on Risk Management of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Treated with Sodium-Glucose Cotransporter (SGLT) Inhibitors
- (2019) Thomas Danne et al. DIABETES CARE
- Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors
- (2019) Susan J. Bersoff-Matcha et al. ANNALS OF INTERNAL MEDICINE
- Effects of sodium‐glucose cotransporter inhibitors on cardiorenal and metabolic systems: Latest perspectives from the outcome trials
- (2019) Soo Lim DIABETES OBESITY & METABOLISM
- Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
- (2019) Hiddo J. L. Heerspink et al. DIABETOLOGIA
- Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials
- (2019) Carmine Zoccali et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- SGLT2 inhibition and glucagon secretion in humans
- (2018) C. Saponaro et al. DIABETES & METABOLISM
- Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
- (2018) Claire C J Dekkers et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection
- (2018) Hiroyuki Umino et al. Scientific Reports
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial
- (2018) Serge A. Jabbour et al. DIABETES CARE
- A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor–dependent pathway after renal injury in mice
- (2018) Yifan Zhang et al. KIDNEY INTERNATIONAL
- Empagliflozin, SGLT2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression
- (2018) Noha A. T. Abbas et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes
- (2018) Kwong-Man Ng et al. Scientific Reports
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETOLOGIA
- Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes
- (2017) Yingying Yang et al. MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials
- (2016) Dandan Li et al. DIABETES OBESITY & METABOLISM
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice
- (2016) Massimo F. Piepoli et al. EUROPEAN HEART JOURNAL
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease
- (2016) Yanling Zhang et al. PLoS One
- Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR
- (2015) Guideline development group et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Type 2 diabetes mellitus
- (2015) Ralph A. DeFronzo et al. Nature Reviews Disease Primers
- Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
- (2014) J.-F. Yale et al. DIABETES OBESITY & METABOLISM
- Functional Role of Glucose Metabolism, Osmotic Stress, and Sodium-Glucose Cotransporter Isoform-Mediated Transport on Na+/H+ Exchanger Isoform 3 Activity in the Renal Proximal Tubule
- (2014) T. D. Pessoa et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment
- (2013) S. Macha et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
- (2013) William T Cefalu et al. LANCET
- Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?
- (2013) Usha Panchapakesan et al. PLoS One
- SGLT2 inhibitors: molecular design and potential differences in effect
- (2011) Masayuki Isaji KIDNEY INTERNATIONAL
- Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members
- (2010) Jian Chen et al. Diabetes Therapy
- The regulation of proximal tubular salt transport in hypertension: an update
- (2009) Xiaoyan Wang et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now